Role of ADAMs in cancer formation and progression.

Hdl Handle:
http://hdl.handle.net/10147/207622
Title:
Role of ADAMs in cancer formation and progression.
Authors:
Duffy, Michael J; McKiernan, Eadaoin; O'Donovan, Norma; McGowan, Patricia M
Affiliation:
Department of Pathology and Laboratory Medicine, St. Vincent's University, Hospital, UCD School of Medicine and Medical Science, University College Dublin, , Dublin, Ireland. MICHAEL.J.DUFFY@UCD.IE
Citation:
Clin Cancer Res. 2009 Feb 15;15(4):1140-4.
Journal:
Clinical cancer research : an official journal of the American Association for, Cancer Research
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207622
DOI:
10.1158/1078-0432.CCR-08-1585
PubMed ID:
19228719
Abstract:
The ADAMs (a disintegrin and metalloproteinase) comprise a family of multidomain transmembrane and secreted proteins. One of their best-established roles is the release of biologically important ligands, such as tumor necrosis factor-alpha, epidermal growth factor, transforming growth factor-alpha, and amphiregulin. Because these ligands have been implicated in the formation and progression of tumors, it might be expected that the specific ADAMs involved in their release would also be involved in malignancy. Consistent with this hypothesis, emerging data from model systems suggest that ADAMs, such as ADAM-9, ADAM-12, ADAM-15, and ADAM-17, are causally involved in tumor formation/progression. In human cancer, specific ADAMs are up-regulated, with levels generally correlating with parameters of tumor progression and poor outcome. In preclinical models, selective ADAM inhibitors against ADAM-10 and ADAM-17 have been shown to synergize with existing therapies in decreasing tumor growth. The ADAMs are thus a new family of potential targets for the treatment of cancer, especially malignancies that are dependent on human epidermal growth factor receptor ligands or tumor necrosis factor-alpha.
Language:
eng
MeSH:
ADAM Proteins/antagonists & inhibitors/chemistry/*physiology; Animals; Disease Progression; Humans; Membrane Proteins/physiology; Neoplasms/*etiology
ISSN:
1078-0432 (Print); 1078-0432 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorDuffy, Michael Jen_GB
dc.contributor.authorMcKiernan, Eadaoinen_GB
dc.contributor.authorO'Donovan, Normaen_GB
dc.contributor.authorMcGowan, Patricia Men_GB
dc.date.accessioned2012-02-01T10:33:09Z-
dc.date.available2012-02-01T10:33:09Z-
dc.date.issued2012-02-01T10:33:09Z-
dc.identifier.citationClin Cancer Res. 2009 Feb 15;15(4):1140-4.en_GB
dc.identifier.issn1078-0432 (Print)en_GB
dc.identifier.issn1078-0432 (Linking)en_GB
dc.identifier.pmid19228719en_GB
dc.identifier.doi10.1158/1078-0432.CCR-08-1585en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207622-
dc.description.abstractThe ADAMs (a disintegrin and metalloproteinase) comprise a family of multidomain transmembrane and secreted proteins. One of their best-established roles is the release of biologically important ligands, such as tumor necrosis factor-alpha, epidermal growth factor, transforming growth factor-alpha, and amphiregulin. Because these ligands have been implicated in the formation and progression of tumors, it might be expected that the specific ADAMs involved in their release would also be involved in malignancy. Consistent with this hypothesis, emerging data from model systems suggest that ADAMs, such as ADAM-9, ADAM-12, ADAM-15, and ADAM-17, are causally involved in tumor formation/progression. In human cancer, specific ADAMs are up-regulated, with levels generally correlating with parameters of tumor progression and poor outcome. In preclinical models, selective ADAM inhibitors against ADAM-10 and ADAM-17 have been shown to synergize with existing therapies in decreasing tumor growth. The ADAMs are thus a new family of potential targets for the treatment of cancer, especially malignancies that are dependent on human epidermal growth factor receptor ligands or tumor necrosis factor-alpha.en_GB
dc.language.isoengen_GB
dc.subject.meshADAM Proteins/antagonists & inhibitors/chemistry/*physiologyen_GB
dc.subject.meshAnimalsen_GB
dc.subject.meshDisease Progressionen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMembrane Proteins/physiologyen_GB
dc.subject.meshNeoplasms/*etiologyen_GB
dc.titleRole of ADAMs in cancer formation and progression.en_GB
dc.contributor.departmentDepartment of Pathology and Laboratory Medicine, St. Vincent's University, Hospital, UCD School of Medicine and Medical Science, University College Dublin, , Dublin, Ireland. MICHAEL.J.DUFFY@UCD.IEen_GB
dc.identifier.journalClinical cancer research : an official journal of the American Association for, Cancer Researchen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.